GenScript Biotech Corporation has announced its role as wet-lab partner for Latent Labs' Latent-X2, a next-generation AI model that designs antibodies and peptides with drug-like properties. GenScript provides high-throughput expression, purification and functional testing of AI-generated molecules, enabling rapid iteration between computational predictions and biological performance. Using its TurboCHO™ High Throughput Platform and cell-free expression systems, GenScript screens AI-designed antibodies, minibinders and peptides to compare candidates and collect data on developability and binding. This reduces reliance on iterative wet-lab optimisation. The collaboration addresses a key industry challenge by accelerating timelines whilst improving likelihood of clinical success. Founded in 2002, GenScript supports over 200,000 customers across 100-plus countries with a team of 5,500-plus employees.

Latent Labs, an AI-based biology platform developer, has emerged from stealth mode, securing $50 million in funding. The round was co-led by Radical Ventures and Sofinnova Partners, with participation from Flying Fish, Isomer, 8VC, Kindred Capital, and Pillar VC. Notable angel investors include Jeff Dean, Aidan Gomez, and Mati Staniszewski. Founded by Simon Kohl, a key figure in the Nobel Prize-winning AlphaFold2 project, Latent Labs aims to revolutionize drug development with generative AI technology.

A new startup from one of the key scientists at Google DeepMind exits stealth today with $50 million in funding.